What does this video actually claim?
@brandonallxn posts a 4-week progress update using the hashtag #glp3, claiming that consistent diet and training are starting to show results. He suggests he's using a "peptide" and promotes the idea that daily consistency leads to eventual progress.
The video doesn't make specific medical claims, but the #glp3 hashtag implies he's using some form of GLP-1 receptor agonist. These medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which are FDA-approved for weight management and diabetes.
Is GLP-3 actually a real thing?
Here's where things get confusing: there's no medication called "GLP-3." The creator likely means GLP-1 receptor agonists, which are well-established medications. GLP-1 stands for glucagon-like peptide-1, a hormone that regulates blood sugar and slows gastric emptying.
The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss at 68 weeks with 2.4mg semaglutide weekly. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed even better results with tirzepatide, achieving up to 22.5% weight loss at the highest dose.
Using incorrect terminology matters because it can mislead viewers about what medications they're actually seeing discussed.
Does consistency really matter with these medications?
The creator gets this part right. GLP-1 receptor agonists work best when combined with lifestyle changes, and consistency is genuinely important for both the medication and accompanying diet modifications.
Clinical trials consistently show better outcomes when patients maintain regular dosing schedules and stick to reduced-calorie diets. The STEP 1 trial included a 500-calorie deficit diet and regular physical activity alongside semaglutide.
However, the medication does most of the heavy lifting. In the same trial, the placebo group with identical lifestyle interventions only achieved 2.4% weight loss versus 14.9% in the semaglutide group.
What's missing from this fitness motivation post?
The creator frames this as a fitness journey without acknowledging he's likely using prescription medication that significantly affects appetite and weight loss. This creates unrealistic expectations for viewers who might think they can achieve similar results through diet and exercise alone.
GLP-1 receptor agonists can cause significant side effects including nausea, vomiting, and diarrhea. About 4-7% of patients discontinue semaglutide due to gastrointestinal issues, according to clinical trial data. The STEP 1 trial reported nausea in 58.8% of participants.
Social media posts about these medications should mention they require medical supervision and aren't appropriate for everyone.
What should viewers actually know?
If someone is considering GLP-1 receptor agonists, they need proper medical evaluation first. These medications are approved for adults with BMI ≥30 or BMI ≥27 with weight-related health conditions.
The results can be impressive, but they're not permanent if you stop the medication. Most clinical trials show weight regain when treatment discontinues, though lifestyle changes can help maintain some benefits.
Getting motivated by transformation posts isn't harmful, but understanding the role of prescription medications in those transformations is important for setting realistic expectations.